Strategic Biopharmaceutical Portfolio Development: An Analysis of Constraint‐Induced Implications

Optimizing the structure and development pathway of biopharmaceutical drug portfolios are core concerns to the developer that come with several attached complexities. These include strategic decisions for the choice of drugs, the scheduling of critical activities, and the possible involvement of third parties for development and manufacturing at various stages for each drug. Additional complexities that must be considered include the impact of making such decisions in an uncertain environment. Presented here is the development of a stochastic multi‐objective optimization framework designed to address these issues. The framework harnesses the ability of Bayesian networks to characterize the probabilistic structure of superior decisions via machine learning and evolve them to multi‐objective optimality. Case studies that entailed three‐ and five‐drug portfolios alongside a range of cash flow constraints were constructed to derive insight from the framework where results demonstrate that a variety of options exist for formulating nondominated strategies in the objective space considered, giving the manufacturer a range of pursuable options. In all cases limitations on cash flow reduce the potential for generating profits for a given probability of success. For the sizes of portfolio considered, results suggest that naïvely applying strategies optimal for a particular size of portfolio to a portfolio of another size is inappropriate. For the five‐drug portfolio the most preferred means for development across the set of optimized strategies is to fully integrate development and commercial activities in‐house. For the three‐drug portfolio, the preferred means of development involves a mixture of in‐house, outsourced, and partnered activities. Also, the size of the portfolio appears to have a larger impact on strategy and the quality of objectives than the magnitude of cash flow constraint.

[1]  Takuji Nishimura,et al.  Mersenne twister: a 623-dimensionally equidistributed uniform pseudo-random number generator , 1998, TOMC.

[2]  Gintaras V. Reklaitis,et al.  Simulation-optimization framework for stochastic optimization of R&D pipeline management , 2003 .

[3]  Evangelos Triantaphyllou,et al.  Multi-Criteria Decision Making Methods , 2000 .

[4]  Suzanne S. Farid,et al.  A multi-criteria decision-making framework for the selection of strategies for acquiring biopharmaceutical manufacturing capacity , 2007, Comput. Chem. Eng..

[5]  Goldberg,et al.  Genetic algorithms , 1993, Robust Control Systems with Genetic Algorithms.

[6]  Kuo-Chu Chang,et al.  Comparison of score metrics for Bayesian network learning , 2002, IEEE Trans. Syst. Man Cybern. Part A.

[7]  Gintaras V. Reklaitis,et al.  A framework for addressing stochastic and combinatorial aspects of scheduling and resource allocation in pharmaceutical R&D pipelines , 2008, Comput. Chem. Eng..

[8]  Gabby Ashton.  Growing pains for biopharmaceuticals , 2001, Nature Biotechnology.

[9]  David E. Goldberg,et al.  Multiobjective hBOA, clustering, and scalability , 2005, GECCO '05.

[10]  Suzanne S. Farid,et al.  Modelling of the biopharmaceutical drug development pathway and portfolio management , 2005, Comput. Chem. Eng..

[11]  Christos T. Maravelias,et al.  A stochastic programming approach for clinical trial planning in new drug development , 2008, Comput. Chem. Eng..

[12]  Suzanne S Farid,et al.  A computer‐aided approach to compare the production economics of fed‐batch and perfusion culture under uncertainty , 2006, Biotechnology and bioengineering.

[13]  I. Karimi,et al.  Regulatory Factors and Capacity-Expansion Planning in Global Chemical Supply Chains , 2004 .

[14]  Yuhong Zhou,et al.  Medium Term Planning of Biopharmaceutical Manufacture using Mathematical Programming , 2005, Biotechnology progress.

[15]  David E. Goldberg,et al.  A Survey of Optimization by Building and Using Probabilistic Models , 2002, Comput. Optim. Appl..

[16]  Suzanne S Farid,et al.  Decision‐Support Tool for Assessing Biomanufacturing Strategies under Uncertainty: Stainless Steel versus Disposable Equipment for Clinical Trial Material Preparation , 2008, Biotechnology progress.

[17]  Heinz Mühlenbein,et al.  The Equation for Response to Selection and Its Use for Prediction , 1997, Evolutionary Computation.

[18]  N. Shah,et al.  Strategic Supply Chain Optimization for the Pharmaceutical Industries , 2001 .

[19]  Jay H. Lee,et al.  Dynamic programming in a heuristically confined state space: a stochastic resource-constrained project scheduling application , 2004, Comput. Chem. Eng..

[20]  David Maxwell Chickering,et al.  Learning Bayesian Networks: The Combination of Knowledge and Statistical Data , 1994, Machine Learning.

[21]  Gary Blau,et al.  Risk management in the development of new products in highly regulated industries , 2000 .

[22]  Suzanne S Farid,et al.  Combining Multiple Quantitative and Qualitative Goals When Assessing Biomanufacturing Strategies under Uncertainty , 2008, Biotechnology progress.

[23]  Nigel J. Titchener-Hooker,et al.  Biopharmaceutical process development: Part I, Information from the first product generation , 2001 .

[24]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[25]  Gintaras V. Reklaitis,et al.  A simulation‐optimization framework for research and development pipeline management , 2001 .

[26]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[27]  R. Werner,et al.  Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.

[28]  Evangelos Triantaphyllou,et al.  Multi-criteria Decision Making Methods: A Comparative Study , 2000 .

[29]  David E. Goldberg,et al.  Linkage Problem, Distribution Estimation, and Bayesian Networks , 2000, Evolutionary Computation.

[30]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.

[31]  J. Pekny,et al.  Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry , 2004 .

[32]  B. S. Piachaud,et al.  Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience , 2002 .

[33]  H. Mühlenbein,et al.  From Recombination of Genes to the Estimation of Distributions I. Binary Parameters , 1996, PPSN.

[34]  Suzanne S. Farid,et al.  Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma , 2007, Comput. Chem. Eng..

[35]  Richard E. Neapolitan,et al.  Learning Bayesian networks , 2007, KDD '07.

[36]  Min Ding,et al.  Valuation and Design of Pharmaceutical R&D Licensing Deals , 2005 .

[37]  Lazaros G. Papageorgiou,et al.  An Aggregation Approach for Capacity Planning under Uncertainty for the Pharmaceutical Industry , 2003 .

[38]  Suzanne S. Farid,et al.  Integrated approach to improving the value potential of biopharmaceutical R&D portfolios while mitigating risk , 2006 .

[39]  Yuhong Zhou,et al.  Application of a Decision‐Support Tool to Assess Pooling Strategies in Perfusion Culture Processes under Uncertainty , 2008, Biotechnology progress.

[40]  J. MacQueen.  Some methods for classification and analysis of multivariate observations , 1967 .

[41]  Sean Nicholson,et al.  Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality , 2002 .

[42]  David E. Goldberg,et al.  The compact genetic algorithm , 1999, IEEE Trans. Evol. Comput..

[43]  Lazaros G. Papageorgiou,et al.  A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry , 2004, Comput. Chem. Eng..

[44]  Vipul Jain,et al.  Resource-Constrained Scheduling of Tests in New Product Development , 1999 .

[45]  I. Grossmann,et al.  Simultaneous Planning for New Product Development and Batch Manufacturing Facilities , 2001 .

[46]  Costas D. Maranas,et al.  Real Options Based Analysis of Optimal Pharmaceutical Research and Development Portfolios , 2002 .

[47]  David E. Goldberg,et al.  Genetic Algorithms in Search Optimization and Machine Learning , 1988 .

[48]  Fernando G. Lobo,et al.  A Survey of Optimization by Building and Using Probabilistic Models , 2000, Proceedings of the 2000 American Control Conference. ACC (IEEE Cat. No.00CH36334).